Skip to content
2000
Volume 4, Issue 4
  • ISSN: 1567-2018
  • E-ISSN: 1875-5704

Abstract

Selective accumulation of an exogenous enzyme or activating agent at a target cell allows use of prodrugs that will be unmasked only at this site. This can reduce the side effects of chemotherapy and allow more potent drugs to be used in various treatments. Examples of this two-step prodrug therapy include antibody- (ADEPT, ADAPT), genetic- (GDEPT, VDEPT) and macromolecule-based approaches (PDEPT, LEAPT). Carbohydrate chemistry and glycobiology feature in each of these areas and is the focus of this review.

Loading

Article metrics loading...

/content/journals/cdd/10.2174/156720107782151278
2007-10-01
2025-10-04
Loading full text...

Full text loading...

/content/journals/cdd/10.2174/156720107782151278
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test